The timeline varies based on individual factors including your starting dose, rate of dose escalation, and genetic predisposition to gastrointestinal sensitivity
Exenatide holds historical significance as the first GLP-1 agonist (FDA 2005) and may still serve as a lower-cost alternative in markets where newer agents are unavailable
"I have to say I am impressed
Wegovy preferred for obesity, Zepbound moved to non-formulary for obesity as of July 2025
There are additional fees for medications: Compounded Semaglutide is $99+ mothly and compounded Tirzepatide is $199+
In addition, even if our results of operations, financial condition and liquidity, and developments in the industry in which we operate are consistent with the forward-looking statements contained in such reports, those results or developments may not be indicative of results or developments in subsequent periods